Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

WHAT'S NEW

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Sep 9 2021

Full Issue

Health Systems Buy Stake In Key Drugmaker Exela; Sanofi Buys Kadmon

11 health systems and group purchaser Premier acquired a stake in Exela Pharma Sciences, a maker of proprietary and generic sterile injectables. Meanwhile, France's Sanofi paid $1.9 billion to buy Kadmon to boost its transplant business. Eliquis drug makers and drug naming are also in the news.

Modern Healthcare: Premier And 11 Health Systems Buy Stake In Specialty Drugmaker

Eleven health systems and the group purchasing organization Premier have acquired a stake in a specialty pharmaceutical company to ensure steady supplies of key drugs. The group now owns a minority stake in Exela Holdings, the holding company of Exela Pharma Sciences, which makes proprietary and generic sterile injectable products. Financial terms were not disclosed. (Bannow, 9/8)

Stat: Sanofi Acquires Kadmon For $1.9 Billion, Adding Transplant Medicine Drug

French drug maker Sanofi said Wednesday that it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business with a newly approved treatment for graft-versus-host disease. The all-cash transaction sees Kadmon shares worth $9.50 per share, or a 79% premium to Tuesday’s closing price. (Feuerstein, 9/8)

FiercePharma: Bristol Myers, Pfizer Score Another Win In Their Eliquis Patent Defense, Protecting The Blockbuster Until 2028 

As a top-selling drug worldwide, Pfizer and Bristol Myers Squibb’s Eliquis is a major target for generic players looking to steal branded sales. But with a new court win, the partners are set for many more years of exclusivity in the lucrative U.S. market. The U.S. Court of Appeals for the Federal Circuit has upheld a prior win for the companies covering two Eliquis patents—the drug’s composition of matter patent and a formulation patent. While the case is subject to another potential appeal, this appeals win sets the companies up to retain U.S. exclusivity until April 1, 2028. (Sagonowsky, 9/7)

KHN: KHN Quiz: Drug Or Not A Drug? 

Face it: Drug names can be kooky. And Comirnaty — the brand-new brand name for the Pfizer-BioNTech covid vaccine — is a candidate for the kookiest. Who hasn’t stumbled over names of prescription drugs, even those you take daily, when put on the spot by a doctor or pharmacist? Take this tongue-in-cheek quiz to see how many brand-name drug names you can pick out from the decoys. (Byrne, 9/6)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF